Nakayama EE - Search Results

1

Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells.

Shimizu J, Sasaki T, Koketsu R, Morita R, Yoshimura Y, Murakami A, Saito Y, Kusunoki T, Samune Y, Nakayama EE, Miyazaki K, Shioda T. Shimizu J, et al. Among authors: nakayama ee. Sci Rep. 2022 Sep 16;12(1):15612. doi: 10.1038/s41598-022-19993-w. Sci Rep. 2022. PMID: 36114224 Free PMC article.

2

Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity.

Ohgimoto S, Shioda T, Mori K, Nakayama EE, Hu H, Nagai Y. Ohgimoto S, et al. Among authors: nakayama ee. J Virol. 1998 Oct;72(10):8365-70. doi: 10.1128/JVI.72.10.8365-8370.1998. J Virol. 1998. PMID: 9733886 Free PMC article.

3

[Host genetic polymorphisms affect HIV-1 diseases].

Shioda T, Nakayama EE. Shioda T, et al. Among authors: nakayama ee. Uirusu. 2000 Jun;50(1):65-72. Uirusu. 2000. PMID: 10998980 Free article. Review. Japanese. No abstract available.

4

A new polymorphism in the promoter region of the human interleukin-16 (IL-16) gene.

Nakayama EE, Wasi C, Ajisawa A, Iwamoto A, Shioda T. Nakayama EE, et al. Genes Immun. 2000;1(4):293-4. doi: 10.1038/sj.gene.6363672. Genes Immun. 2000. PMID: 11196708

5

Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5.

Shioda T, Nakayama EE, Tanaka Y, Xin X, Liu H, Kawana-Tachikawa A, Kato A, Sakai Y, Nagai Y, Iwamoto A. Shioda T, et al. Among authors: nakayama ee. J Virol. 2001 Apr;75(7):3462-8. doi: 10.1128/JVI.75.7.3462-3468.2001. J Virol. 2001. PMID: 11238872 Free PMC article.

6

Protective effect of interleukin-4 -589T polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load.

Nakayama EE, Meyer L, Iwamoto A, Persoz A, Nagai Y, Rouzioux C, Delfraissy JF, Debre P, McIlroy D, Theodorou I, Shioda T; SEROCO Study Group. Nakayama EE, et al. J Infect Dis. 2002 Apr 15;185(8):1183-6. doi: 10.1086/339825. Epub 2002 Mar 20. J Infect Dis. 2002. PMID: 11930331

7

[Host genetic polymorphisms in the pathogenesis of HIV-1 disease].

Nakayama EE, Shioda T. Nakayama EE, et al. Nihon Rinsho. 2002 Apr;60(4):724-31. Nihon Rinsho. 2002. PMID: 11968779 Review. Japanese.

8

New Rev-transport inhibitor with anti-HIV activity from Valerianae Radix.

Murakami N, Ye Y, Kawanishi M, Aoki S, Kudo N, Yoshida M, Nakayama EE, Shioda T, Kobayashi M. Murakami N, et al. Among authors: nakayama ee. Bioorg Med Chem Lett. 2002 Oct 21;12(20):2807-10. doi: 10.1016/s0960-894x(02)00624-8. Bioorg Med Chem Lett. 2002. PMID: 12270151

9

A CCR2-V64I polymorphism affects stability of CCR2A isoform.

Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. Nakayama EE, et al. AIDS. 2004 Mar 26;18(5):729-38. doi: 10.1097/00002030-200403260-00003. AIDS. 2004. PMID: 15075507

10

A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection.

Nakayama EE, Miyoshi H, Nagai Y, Shioda T. Nakayama EE, et al. J Virol. 2005 Jul;79(14):8870-7. doi: 10.1128/JVI.79.14.8870-8877.2005. J Virol. 2005. PMID: 15994780 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

137 results

Search Page

Filters